A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
Clinical trial NCT07159763 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07159763
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-25
- Primary completion
- 2027-06-01
- Enrollment
- 10000
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.